Investment, Funding & Disinvestments

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

The plan follows Arada’s acquisition of a controlling stake in Reem Hospital, marking the company’s entry into the healthcare sector as it expands its presence across non-residential industries.

The new campus brings a modern approach to training healthcare professionals by embedding artificial intelligence, data analytics, and digital health tools directly into clinical learning.

Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.

The initiative will also involve coordination with World Health Organization, Africa Centres for Disease Control and Prevention, and UNICEF to ensure alignment with national outbreak response plans and immunization priorities.

The equipment was officially received by Ministry of Health Permanent Secretary for Donor Coordination, Dr. George Sinyangwe, during a handover ceremony attended by senior government officials and public health leaders.

The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).

The company officially listed on the Hong Kong Stock Exchange on June 5, achieving a market valuation of approximately HK$10.7 billion (US$1.37 billion) following its debut.

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.